Author

Emily G. Smith

Purdue University West Lafayette

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Brittany L. Allen-PeterseniD· 3 shared Brittany N. HeiliD· 3 shared Claire M. PfefferiD· 2 shared Emma H. DoudiD· 2 shared Garima BaraliD· 2 shared Kasi HanseniD· 2 shared Lauren E. GartenhausiD· 2 shared Sydney J. CliffordiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Brittany L. Allen-PetersenORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification, optimization, and structural elucidation of chloroacetamide scaffold as covalent inhibitors for Ubiquitin C-terminal Hydrolase L3

Nagabhushana C. Beeralingappa, Mengyao Lu, Rishi S. Patel, Nipuni M. Pannala, Alisha Dhiman, Brittany N. Heil, Ryan D. Imhoff, Emily G. Smith, Mei B Bahler, Haley L Marsden, Brittany L. Allen-Petersen, Mike Wendt, Chittaranjan Das, Daniel Patrick Flaherty

This study identifies and optimizes a chloroacetamide scaffold as a covalent inhibitor for UCHL3, supported by structural and biochemical validation.

bioRxiv · May 29, 2026 · PreprintPharmacology & Toxicology

Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung Cancer

Brittany N. Heil, Garima Baral, Claire M. Pfeffer, Mei B. Bahler, Sanika S. Gulavani, Emily G. Smith, Lauren E. Gartenhaus, Anna K. Darling, Sydney J. Clifford, Whitney R. Smith-Kinnaman, Kasi Hansen, Emma H. Doud, Gaganpreet K. Mall, Aaron N. Hata, Nicole L. Anderson, , Brittany L. Allen-Petersen

This study shows that suppressing PP2A-B56α promotes EMT in EGFR mutant NSCLC by reducing epithelial markers and increasing mesenchymal markers, leading to migratory and invasive phenotypes.

Oncogene · Apr 11, 2026Peer-reviewedCancer Biology

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC

Claire M. Pfeffer, Sydney J. Clifford, Saadia A. Karim, Ella Rose D. Chianis, Brittany N. Heil, Lauren E. Gartenhaus, Emma F. Kay, Garima Baral, Elizabeth G. Hoffman, Sagar M. Utturkar, Harish Kothandaraman, Whitney R. Smith-Kinnaman, Kasi Hansen, Emily G. Smith, Elisabeth Porter, , Brittany L. Allen-Petersen

This study shows that activating PP2A-B56 in PDAC increases EGFR signaling and promotes tumor growth, suggesting a new therapeutic target.

bioRxiv · Jul 18, 2025 · PreprintCancer Biology